Cancer Type: Malignant Hematology
Study Type: Treatment
Phase: Phase II
Principal Investigator: Komrokji, Rami
A Phase 2, Multicenter, Open-Label Study To Evaluate The Efficacy And Safety Of Luspatercept (Ace-536) In Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis And Anemia With And Without Red Blood Cell-Transfusion Dependence
The main purpose of this study is to see if people with Myeloproliferative Neoplasm (MPN) Associated myelofibrosis that may or may not need blood transfusions will experience an increase of their hemoglobin or stop needing blood transfusions by taking luspatercept. The safety of luspatercept will be also evaluated in this study.
Primary Objective: The primary objective of the study is to evaluate the efficacy and safety of luspatercept for the treatment of anemia in subjects with myeloproliferative neoplasm (MPN)-associated myelofibrosis with and without red blood cell (RBC)-transfusion dependence. Secondary Objectives: To evaluate the safety of luspatercept in MPN-associated myelofibrosis. To evaluate the effect of luspatercept in MPN-associated myelofibrosis: - on the time to and duration of anemia response - on frequency of RBC transfusions and transfusion dependence - on symptom response improvement via the Myelofibrosis Symptom Assessment Form (MF-SAF) v4 - on health-related quality of life (HRQoL) via the EQ-5D-5L and Functional Assessment of Cancer Therapy - Anemia (FACT-An) questionnaires. To evaluate population pharmacokinetics of luspatercept in subjects with MPNassociated myelofibrosis with and without RBC-transfusion dependence. Explanatory Objectives: To explore the relationship between luspatercept exposure and measures of efficacy and toxicity. To explore biomarkers related to efficacy parameters and markers related to mechanism of action of luspatercept. - Activin receptor IIB ligands such as growth differentiation factor 11 (GDF11) and, - Activin B, - Inflammatory cytokines such as interleukin (IL)-6, IL-8, and tumor necrosis factor-alpha (TNF-a), - Serum markers related to fibrogenesis such as transforming growth factor-beta 1 (TGF-b1) and thrombopoietin (TPO), - Circulating blasts (CD34+ cells), - Gene expression profiling or other similar evaluation related to drug mechanism of action. To explore MPN-associated myelofibrosis-related mutations relative to disease progression and/or drug response.
ACE-536 (Luspatercept); Luspatercept ()
If you are interested in learning more about clinical trials, our clinical trial navigators can discuss your options and recommend opportunities that may be suitable for you. Call 813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form.
Back to top
Please call 1-888-663-3488 for support from a Moffitt representative. New Patients and Healthcare Professionals can submit an online form by selecting the appropriate button below. Existing patients can call 1-888-663-3488. Click here for a current list of insurances accepted at Moffitt.
NEW PATIENTS To request a new patient appointment, please fill out the online form or call 1-888-663-3488.
REFERRING PHYSICIANS Providers and medical staff can refer patients by submitting our online referral form.
Moffit now offers Virtual Visits for patients. If you are eligible for a virtual appointment, our scheduling team will discuss this option further with you.
Moffitt Cancer Center is committed to the health and safety of our patients and their families. For more information on how we’re protecting our new and existing patients, visit our COVID-19 Info Hub
Our patient services specialists can assist you with scheduling an appointment, questions about medical records, insurance, billing and more.
Patient Appointment Center Hours: 7 a.m. to 7 p.m. Monday - Friday; 8 a.m. to noon Saturday